CN104736555B - 结核分枝杆菌疫苗 - Google Patents

结核分枝杆菌疫苗 Download PDF

Info

Publication number
CN104736555B
CN104736555B CN201380054841.4A CN201380054841A CN104736555B CN 104736555 B CN104736555 B CN 104736555B CN 201380054841 A CN201380054841 A CN 201380054841A CN 104736555 B CN104736555 B CN 104736555B
Authority
CN
China
Prior art keywords
vaccine
mycobacterium
protein
fusion protein
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201380054841.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN104736555A (zh
Inventor
克劳斯·埃格德
艾达·罗森克兰达斯
特吕克·蒂·吉姆·坦·候昂
彼得·安德森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Serum Institute
Original Assignee
National Serum Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Serum Institute filed Critical National Serum Institute
Publication of CN104736555A publication Critical patent/CN104736555A/zh
Application granted granted Critical
Publication of CN104736555B publication Critical patent/CN104736555B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201380054841.4A 2012-10-23 2013-10-18 结核分枝杆菌疫苗 Expired - Fee Related CN104736555B (zh)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
DKPA201200652 2012-10-23
DKPA201200653 2012-10-23
DKPA201200654 2012-10-23
DKPA201200654 2012-10-23
DKPA201200653 2012-10-23
DKPA201200652 2012-10-28
DKPA201300477 2013-08-23
DKPA201300477 2013-08-23
PCT/DK2013/000070 WO2014063704A2 (en) 2012-10-23 2013-10-18 M. tuberculosis vaccines

Publications (2)

Publication Number Publication Date
CN104736555A CN104736555A (zh) 2015-06-24
CN104736555B true CN104736555B (zh) 2019-06-21

Family

ID=49679267

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380054841.4A Expired - Fee Related CN104736555B (zh) 2012-10-23 2013-10-18 结核分枝杆菌疫苗

Country Status (8)

Country Link
US (1) US9526773B2 (enExample)
EP (1) EP2912056B1 (enExample)
JP (1) JP6470179B2 (enExample)
CN (1) CN104736555B (enExample)
BR (1) BR112015009070A2 (enExample)
IN (1) IN2015DN03962A (enExample)
WO (1) WO2014063704A2 (enExample)
ZA (1) ZA201503467B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2695462C2 (ru) * 2014-01-09 2019-07-23 Трансген Са Гибридизация гетероолигомерных микобактериальных антигенов
JP2017513860A (ja) * 2014-04-24 2017-06-01 スタテンス セールム インスティトゥート 新規結核菌（ｍ．ｔｕｂｅｒｃｕｌｏｓｉｓ）ワクチン
CN108136000B (zh) 2015-09-30 2022-11-08 勃林格殷格翰动物保健有限公司 经改良的模块化抗原转运分子及其在动物中的用途
CN105218681B (zh) * 2015-10-21 2019-06-25 中山大学 一种用于诱导外周血单个核细胞产生结核特异性细胞因子的融合蛋白
CN105218680B (zh) * 2015-10-21 2019-06-25 中山大学 一种用于诱导外周血单个核细胞产生细胞因子的结核分支杆菌融合蛋白
CN105567660B (zh) * 2016-01-08 2018-11-20 中国人民解放军第四军医大学 一种大肠杆菌重组表达结核分枝杆菌Rv2837c活性蛋白的方法及其应用
US20200148729A1 (en) * 2016-05-21 2020-05-14 Infectious Disease Research Institute Compositions and Methods for Treating Secondary Tuberculosis and Nontuberculosis Mycobacterium Infections
EP3474889A4 (en) 2016-06-22 2020-04-29 International AIDS Vaccine Initiative, Inc. RECOMBINANT CYTOMEGALOVIRUS VECTORS FOR USE AS TUBERCULOSIS VACCINES
EP3555630B1 (en) 2016-12-14 2023-05-31 Becton, Dickinson and Company Methods and compositions for obtaining a tuberculosis assessment in a subject
KR102589422B1 (ko) * 2017-01-09 2023-10-13 바이오뮤넥스 파마슈티컬스 다중특이적 항체를 제조하기 위한 폴리펩티드 링커
WO2019079155A1 (en) 2017-10-17 2019-04-25 International Aids Vaccine Initiative, Inc. CASSETTES OF ANTIGENS OF TUBERCULOSIS
PH12021553146A1 (en) * 2019-06-14 2024-04-22 Statens Seruminstitut Fusion proteins for tuberculosis vaccines
US20220280630A1 (en) * 2019-08-01 2022-09-08 Trustees Of Tufts College Vaccine compositions and methods of selecting antigens
CN110590958B (zh) * 2019-09-11 2021-04-13 中国人民解放军总医院第八医学中心 一种串联多肽及其在抗结核分枝杆菌的免疫保护中的应用
KR20240153581A (ko) 2022-02-21 2024-10-23 스태튼스 세룸 인스티튜트 신규한 양이온 어주번트 조성물
CN115300618A (zh) * 2022-05-11 2022-11-08 中国农业大学 基于牛β防御素5的结核疫苗及其在预防结核病中的应用
CN115184603B (zh) * 2022-06-30 2024-02-06 首都医科大学附属北京胸科医院 EspC蛋白在制备结核分枝杆菌分离或富集产品中的应用
KR20250087737A (ko) * 2023-12-06 2025-06-17 주식회사 미코라파 결핵균에 대한 살균면역을 유도하는 융합단백질을 포함하는 결핵 백신 조성물
CN118108815B (zh) * 2024-04-23 2024-07-23 成都康华生物制品股份有限公司 结核分枝杆菌多免疫原抗原、编码其的mRNA、应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1304451A (zh) * 1998-04-07 2001-07-18 科里克萨公司 结核杆菌抗原融合蛋白及其应用
WO2003085098A2 (en) * 2002-04-05 2003-10-16 Institut Pasteur Identification of virulence associated regions rd1 and rd5 enabling the development of improved vaccines of m. bovis bcg and m. microti
CN102413837A (zh) * 2009-04-24 2012-04-11 国立血清研究所 预防再激活的结核病tb疫苗

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012057904A1 (en) * 2010-10-27 2012-05-03 Infectious Disease Research Institute Mycobacterium tuberculosis antigens and combinations thereof having high seroreactivity

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1304451A (zh) * 1998-04-07 2001-07-18 科里克萨公司 结核杆菌抗原融合蛋白及其应用
WO2003085098A2 (en) * 2002-04-05 2003-10-16 Institut Pasteur Identification of virulence associated regions rd1 and rd5 enabling the development of improved vaccines of m. bovis bcg and m. microti
CN102413837A (zh) * 2009-04-24 2012-04-11 国立血清研究所 预防再激活的结核病tb疫苗

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
A multistage tuberculosis vaccine that confers efficient protection before and after exposure;Claus Aagaard等;《nature medicine》;20110123;第17卷(第2期);第189-194页 *
Exchanging ESAT6 with TB10.4 in an Ag85B Fusion Molecule-Based Tuberculosis Subunit Vaccine: Efficient Protection and ESAT6-Based Sensitive Monitoring of Vaccine Efficacy;Jes Dietrich等;《The Journal of Immunology》;20050501;第174卷(第10期);第6332-6339页 *
TB vaccines: current status and future perspectives;Claus Aagaard等;《Immunology and Cell Biology》;20090407;第87卷(第4期);第279-286页 *
佐剂DDA和MPL对提高结核杆菌组合DNA疫苗免疫效果的比较研究;余大海等;《生物化学与生物物理进展》;20050820;第32卷(第8期);第765-770页 *
结核分枝杆菌RD-1区编码蛋白的结构和功能;李浩等;《生物化学与生物物理进展》;20091015;第36卷(第10期);第1260-1266页 *
结核疫苗优势抗原ESAT6、CFP10的分子生物学基础及应用研究进展;范琴等;《生物医学工程学杂志》;20120425;第29卷(第2期);第392-396页 *

Also Published As

Publication number Publication date
WO2014063704A8 (en) 2015-07-30
US20150290311A1 (en) 2015-10-15
CN104736555A (zh) 2015-06-24
EP2912056B1 (en) 2020-02-12
JP6470179B2 (ja) 2019-02-13
ZA201503467B (en) 2016-11-30
JP2015536309A (ja) 2015-12-21
WO2014063704A2 (en) 2014-05-01
BR112015009070A2 (pt) 2017-07-04
US9526773B2 (en) 2016-12-27
EP2912056A2 (en) 2015-09-02
WO2014063704A3 (en) 2014-06-19
IN2015DN03962A (enExample) 2015-10-02

Similar Documents

Publication Publication Date Title
CN104736555B (zh) 结核分枝杆菌疫苗
Zhu et al. Tuberculosis vaccines: Opportunities and challenges
Brodin et al. ESAT-6 proteins: protective antigens and virulence factors?
ES2714383T3 (es) Vacuna TB contra la tuberculosis para impedir la reactivación
Valbuena et al. Approaches to vaccines against Orientia tsutsugamushi
Hewinson et al. Use of the bovine model of tuberculosis for the development of improved vaccines and diagnostics
ES2229220T3 (es) Vacuna contra la tuberculosis.
Barazzone et al. Revisiting the development of vaccines against pathogenic Leptospira: innovative approaches, present challenges, and future perspectives
US10004793B2 (en) M.tuberculosis vaccines
EP1379552A1 (en) Toll-like receptor 5 ligands and methods of use
Vernel-Pauillac et al. Recent findings related to immune responses against leptospirosis and novel strategies to prevent infection
WO2001079274A2 (en) Tuberculosis antigens and methods of use thereof
CN108059660A (zh) 新型组合物和方法
Kwon et al. BCG-booster vaccination with HSP90-ESAT-6-HspX-RipA multivalent subunit vaccine confers durable protection against hypervirulent Mtb in mice
Fan et al. Differential immunogenicity and protective efficacy of DNA vaccines expressing proteins of Mycobacterium tuberculosis in a mouse model
Roupie et al. Immunogenicity and protective efficacy of DNA vaccines encoding MAP0586c and MAP4308c of Mycobacterium avium subsp. paratuberculosis secretome
Stabel et al. Evaluation of protection in a mouse model after vaccination with Mycobacterium avium subsp. paratuberculois protein cocktails
US8551497B2 (en) Microbial vaccine and vaccine vector
Azama et al. Antigenic outer membrane proteins prediction of Pasteurella multocida serotype B: 2
Luan et al. Exploring the immunogenicity of Rv2201-519: A T-cell epitope-based antigen derived from Mycobacterium tuberculosis AsnB with implications for tuberculosis infection detection and vaccine development
Mukherjee et al. Cloning of the gene encoding a protective Mycobacterium tuberculosis secreted protein detected in vivo during the initial phases of the infectious process
Gao et al. A novel DNA vaccine containing multiple TB‐specific epitopes cast in a natural structure elicits enhanced Th1 immunity compared with BCG
CN101248084A (zh) 包含潜伏感染阶段期间所表达的抗原的结核疫苗
Eraghi et al. and Azar Motamedi Boroojeni1
CN117683144A (zh) 一种结核分支杆菌融合抗原及其亚单位疫苗

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Address after: Copenhagen, Denmark

Applicant after: National Serum Institute

Address before: Copenhagen, Denmark

Applicant before: Statens Seruminstitut

COR Change of bibliographic data
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20190621

Termination date: 20201018